Drug firm Cipla today reported a consolidated net profit of Rs 434.95 crore for the September quarter mainly on account of robust domestic sales.
The company had posted a net profit of Rs 369.64 crore for the corresponding period of the previous fiscal, Cipla said in a BSE filing.
"A progressive recovery for Cipla, as we recorded strong growth momentum across key markets. Our US growth is getting a major boost with initiation of much-awaited product approvals," Cipla MD and Global CEO Umang Vohra said.
The domestic business witnessed significant ramp-up in- line with strong off-take. The efforts to improve cost efficiency continue to yield benefits, he added.
Consolidated total income of the company stood at Rs 4,195.74 crore for the quarter under consideration. It was Rs 3,778.25 crore for the same period a year ago.
The company said revenue from operations for the quarter and half year ended September 30, 2017 are not comparable with corresponding previous periods.
The quarter saw significant growth in the India business, which grew by 12 per cent year-on-year, Cipla said.
Shares of Cipla today closed 7.18 per cent down at Rs 608.35 per scrip on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
